CHAPLE Disease

CHAPLE disease-CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy-is a rare, inherited disorder caused by pathogenic variants in CD55. Loss of CD55-mediated complement regulation can produce intestinal protein loss, low serum albumin, edema, gastrointestinal symptoms, infections, and thrombotic complications. Diagnosis and management require coordinated expertise in clinical immunology, gastroenterology, hematology, genetics, and specialist laboratory medicine.

The CHAPLE disease landscape is shifting from symptom-focused management toward earlier molecular diagnosis and complement-directed care. Persistent hypoalbuminemia, unexplained protein-losing enteropathy, recurrent infections, and thrombosis-particularly when occurring together or in more than one family member-are important prompts for immunologic and genetic evaluation. Greater use of exome or genome sequencing, functional complement assessment, and international case collaboration is improving recognition of an ultra-rare condition that may otherwise be misclassified as inflammatory bowel disease, primary intestinal lymphangiectasia, immunodeficiency, or another enteropathy.

Artificial intelligence may support CHAPLE disease by identifying combinations of rare clinical findings in electronic records, prioritizing patients for genetic testing, and assisting variant interpretation alongside validated laboratory and clinical review. Natural-language processing can help connect gastrointestinal, immunologic, thrombotic, and family-history information that is often recorded across specialties. AI can also aid literature surveillance, registry curation, and trial eligibility screening, but its outputs require specialist oversight because the evidence base is small, datasets are vulnerable to bias, and diagnosis cannot be established from an algorithm alone.

In North America, established rare-disease centers, genetic testing access, and multidisciplinary care can support diagnosis, although referral delays and insurance or authorization barriers remain relevant. Europe benefits from cross-border rare-disease networks and specialist immunology services, while differences in national reimbursement and access can affect continuity. Asia-Pacific combines advanced centers in countries such as Japan, Australia, and South Korea with substantial variation in specialist availability and genetic testing capacity. Latin America, the Middle East, and Africa may face greater constraints in confirmatory testing, registries, and access to highly specialized care, making referral networks, telemedicine, and local clinician education especially important.

Within the European Union, harmonized referral pathways, genomic infrastructure, and cross-border expertise can strengthen care, although implementation differs among member states. G7 countries generally have strong research and specialist capabilities, with ongoing challenges involving equitable access and fragmented data. ASEAN members may benefit from regional laboratory partnerships and shared rare-disease protocols. BRICS countries represent diverse health-system contexts and can advance diagnosis through collaborative registries and genomic networks. GCC states can leverage centralized specialist services and family-genomics programs, while NATO members may benefit from interoperable research and clinical networks, without assuming uniform health-policy or reimbursement arrangements across the group.

The United States and Canada have specialized immunology, gastroenterology, and genetics services, but access and coverage may vary by jurisdiction. Brazil and Mexico can expand recognition through referral-center collaboration and improved access to molecular testing. The United Kingdom, France, Germany, Italy, and Spain have established rare-disease and genomic-medicine infrastructures, with national differences in referral, reimbursement, and specialist availability. Australia, Japan, and South Korea have advanced tertiary-care capabilities, while coordinated rare-disease pathways remain important. China and India have large clinical populations and growing genomic capacity, but regional disparities in specialist access and confirmatory testing persist. Russia has relevant tertiary and genetic expertise, with access shaped by geography and system organization.

Industry and healthcare leaders should prioritize five actions: establish diagnostic algorithms for protein-losing enteropathy with immune and thrombotic features; expand access to validated CD55 sequencing and confirmatory functional testing; create multidisciplinary referral pathways linking gastroenterology, immunology, hematology, and genetics; develop longitudinal registries that capture infections, albumin loss, thrombosis, growth, treatment response, and safety; and support patient education focused on urgent symptoms, nutrition, infection prevention, and family evaluation. Evidence generation should use transparent endpoints and natural-history data appropriate to an ultra-rare disorder.

This executive summary synthesizes established clinical and genetic knowledge about CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy. The approach emphasizes peer-reviewed case reports and series, authoritative rare-disease and clinical-genetics resources, published diagnostic criteria and laboratory methods, and documented care patterns. Regional, group, and country observations are framed as health-system and research-capacity considerations rather than quantitative comparisons. No market estimates, forecasts, market shares, or company-specific claims are included.

CHAPLE disease requires a high index of suspicion because gastrointestinal protein loss may precede recognition of the underlying complement-regulation defect. Earlier genetic confirmation, coordinated specialty care, careful management of infection and thrombosis risk, and structured longitudinal follow-up can reduce diagnostic delay and improve clinical decision-making. Progress will depend on connecting rare-disease expertise across regions, strengthening equitable access to testing, and generating high-quality evidence without overstating conclusions from limited patient populations.